| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
Last patient, last visit of the 6-month treatment period in the Phase 3 DUET-AD study is scheduled for December 31, 2026, with database lock on February 8, 2027, and data readout in March 2027 |
| 05 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
1 INTRODUCTORY. Annovis Bio, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Underwriting Agreement (this “Agreement”), to the underwriter named in Schedule A hereto (the “Underwriter”), (i) ... |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Annovis Bio, Inc. (the “Company”) is providing the following information about its preliminary cash and cash equivalents as of September 30, 2026. Based on preliminary estimates and currently available information, the Company estimates ... |
| 04 Nov 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
I, CHARUNI PATIBANDA-SANCHEZ, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “ANNOVIS BIO, INC.”, FILED IN THIS OFFICE ON THE FOURTH DAY OF NOVEMB... |
| 30 Oct 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Regulation FD Disclosure
MALVERN, PA – October 30, 2026 – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as ... |
| 20 Oct 2026 |
8-K: Other Events
Due to a typographical error in the Company’s proxy statement for its annual meeting of stockholders held on June 17, 2026, the Company is filing this Current Report on Form 8-K to correct the disclosure of audit fees. The corrected fees... |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections. |
| 10 Jul 2026 |
8-K: Other Events
Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections |
| 17 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2026, Annovis Bio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) virtually. At the Annual Meeting, five proposals were submitted to the Company’s stockholders and all matters voted u... |
| 20 May 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
1. INTRODUCTORY. Annovis Bio, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Underwriting Agreement (this “Agreement”), to the underwriter named in Schedule A hereto (the “Underwriter”), (i)... |
| 15 May 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026 |
| 10 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
1. INTRODUCTORY. Annovis Bio, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Underwriting Agreement (this “Agreement”), to the underwriter named in Schedule A hereto (the “Underwriter”), (i)... |
| 25 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements |
| 16 Mar 2026 |
8-K: Results of Operations and Financial Condition
Malvern, PA, March 16, 2026 -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Al... |
| 12 Feb 2026 |
8-K: Regulation FD Disclosure
Malvern, PA, Feb. 12 -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer... |
| 28 Jan 2026 |
8-K: Regulation FD Disclosure
NYSE: ANVS Annovis Webinar January 28, 2026 Presenter: Maria Maccecchini, Ph.D., President and CEO |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
Malvern, Pa., Nov. 12, 2025 – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) an... |
| 28 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Securities Purchase Agreement (this “Agreement”) is dated as of October 28, 2025, between Annovis Bio, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its su... |
| 14 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
This Securities Purchase Agreement (this “Agreement”) is dated as of October 10, 2025, between Annovis Bio, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its su... |
| 29 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheime... |
Loading...